[Chemotherapy of the small cell lung cancer using polyplatillen].
The experience of application of a new antitumoral platinum--containing preparation--polyplatyllen--in the treatment of the small cell pulmonary cancer was summarized. It was established, that the security profile of polyplatyllen is more favourable and efficacy in the treatment of the extended small cell pulmonary cancer is higher, than those of the standard scheme of treatment using cisplatinum and etoposide. The quality of life of the patients, while application of polyplatyllen, is more stable, than in application of the combined prescription of cisplatinum and etoposide.
Iatsenko
L D
LD
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003131:Combined Modality Therapy; D018736:DNA Adducts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D018736:DNA Adducts; C057270:cisplatin-DNA adduct; D005047:Etoposide; D002945:Cisplatin